The only patent I'm aware of, that Repligen has exclusive rights to with relevance to this pathway, is # 6,685,941. It pertains to CTLA-4Ig (a fusion protein between the extracellular domain of CTLA-4 receptor and the Fc fragment of a human IgG), with essentially an immunosuppressive effect. Contrariwise, Ipilimumab (an anti-CLA-4 mAb binds to CTLA-4 Helper T cells ), is upregulating the immune response and enhances the anticancer immune defense. In addition, the '941 patent claims are for treating autoimmune diseases, not cancer.
News 
Market Data 
Discover 
